Biological therapy of salivary duct carcinoma
- 11 April 2008
- journal article
- case report
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 123 (2) , 250-252
- https://doi.org/10.1017/s0022215108002314
Abstract
Background: The incidence of human epidermal growth factor receptor 2 positivity in salivary duct carcinoma ranges from 25 to 100 per cent and is associated with a poor outcome. Salivary duct carcinoma has significant pathological similarities to ductal carcinoma of the breast.Keywords
This publication has 13 references indexed in Scilit:
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- Clinical and immunohistologic typing of salivary duct carcinomaCancer, 2005
- Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast CancerJNCI Journal of the National Cancer Institute, 2004
- Expression of HER‐2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in‐situ hybridization and immunohistochemistryHistopathology, 2004
- Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumourJournal of Clinical Pathology, 2003
- Expression of HER‐2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in‐situ hybridization and immunohistochemistryHistopathology, 2003
- Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinomaHuman Pathology, 1996
- The neu-oncogene: More than a prognostic indicator?Human Pathology, 1994
- Salivary duct carcinomaOral Surgery, Oral Medicine, Oral Pathology, 1994
- Salivary duct carcinoma—a highly aggressive salivary gland tumour with overexpression of c‐erB‐2The Journal of Pathology, 1994